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Abstract
Background: Despite our substantial understanding of molecular mechanisms and gene mutations involved in
cancer, the technical approaches for diagnosis and prognosis of cancer are limited. In routine clinical diagnosis of
cancer, the procedure is very basic: nuclear morphology is used as a common assessment of the degree of
malignancy, and hence acts as a prognostic and predictive indicator of the disease. Furthermore, though the
atypical nuclear morphology of cancer cells is believed to be a consequence of oncogenic signaling, the molecular
basis remains unclear. Another common characteristic of human cancer is aneuploidy, but the causes and its role
in carcinogenesis are not well established.
Methods: We investigated the expression of the nuclear envelope proteins lamin A/C in ovarian cancer by
immunohistochemistry and studied the consequence of lamin A/C suppression using siRNA in primary human
ovarian surface epithelial cells in culture. We used immunofluorescence microscopy to analyze nuclear morphology,
flow cytometry to analyze cellular DNA content, and fluorescence in situ hybridization to examine cell ploidy of the
lamin A/C-suppressed cells.
Results: We found that nuclear lamina proteins lamin A/C are often absent (47%) in ovarian cancer cells and
tissues. Even in lamin A/C-positive ovarian cancer, the expression is heterogeneous within the population of tumor
cells. In most cancer cell lines, a significant fraction of the lamin A/C-negative population was observed to intermix
with the lamin A/C-positive cells. Down regulation of lamin A/C in non-cancerous primary ovarian surface epithelial
cells led to morphological deformation and development of aneuploidy. The aneuploid cells became growth
retarded due to a p53-dependent induction of the cell cycle inhibitor p21.
Conclusions: We conclude that the loss of nuclear envelope structural proteins, such as lamin A/C, may underlie
two of the hallmarks of cancer - aberrations in nuclear morphology and aneuploidy.
Background
A deformed and enlarged nuclear morphology is a com-
mon characteristic of cancer cells, and the “roundness”
of the nucleus is a good indicator to distinguish benign,
low grade, and malignant cells [1,2]. In the clinical set-
ting, the morphology of the nucleus is used universally
for diagnostic and prognostic prediction of malignancies
of tumor cells, referred to as “nuclear grade” [1,2].
The most well known diagnostic test based on cell and
nuclear morphology is the cervical Papanicolaou (PAP)
smear test [3]. In PAP smears, cells collected from a
swab of the cervix are examined under microscope to
determine the presence of large and atypical nuclei,
which serves as an initial diagnosis of cervical or uterine
cancer. The simple procedure was invented in the
1930s, widely implemented by the 1960s, still universally
practiced worldwide today, and is credited for saving
millions of lives.
In the last 5 decades, much research has been devoted
to understand the molecular basis for the atypical and
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enlarged nucleus that accompanies malignancy. In ovar-
ian cancer, nuclear size and morphology correlate with
the degree of genetic changes and can be used to distin-
guish low- from high-grade serous cancer, as well as to
predict outcome [4-6]. Molecular changes in the nuclear
matrix and/or nuclear envelope have been postulated,
and deformation of nuclear morphology was shown to
associate with oncogenic signaling [7-9], but no definite
conclusions have been reached regarding the molecular
basis of nuclear deformation in malignant cells [1,10].
Another hallmark of cancer cells, first recognized over
one hundred years ago by Boveri [11,12] is aneuploidy,
or an abnormal and unbalanced number of chromo-
somes compared to diploid normal cells. The majority
(around 90%) of human ovarian cancers are aneuploid
and possess a hyperdiploid (> 46) to subtetraploid (< 96)
chromosome number http://www.ncbi.nlm.nih.gov/sky/
skyweb.cgi?form_type=submitters. Cancer cells within
one tumor or cell line are not uniform in chromosomal
number, indicating the presence of chromosomal
numerical instability in cancer cells [13]. Although an
association between aneuploidy and malignancy has
been well recognized, the causes and significance of
aneuploidy in cancer remain unsettled [14-17]. Forma-
tion of aneuploid cells was found to be an early event in
the development of ovarian cancer, suggesting aneu-
ploidy contributed to cancer initiation [18]. Mitotic fail-
ure, tetraploid intermediates, and subsequent
unbalanced cytokineses are the most common cause of
aneuploidy [19-21]. Frequently, tetraploid cells are the
products of mitotic regression after failed cytokinesis
and the intermediates that produce aneuploid cells in
subsequent mitotic events [20]. Nevertheless, in ovarian
cancer, the molecular basis for the causes of aneuploidy
is largely unknown.
In mammalian cells, loss or mutation of nuclear envel-
ope structural proteins such as emerin [22] or lamin A/C
[23] produces nuclear morphological deformation. Lamin
A and lamin C are differentially spliced forms of the
same gene and differ only at the C-terminal domain [24].
Lamin A/C expression is absent in embryonic stem cells
and early embryos, and is progressively expressed in
nearly all tissues at later developmental stages [25]. The
initiation of lamin A/C expression is associated with cell
differentiation, which suggests that lamin A/C expression
may serve as a limit on the plasticity of cells for further
developmental events [25,26]. Additionally, the cell types
that seem to lack lamin A/C, such as embryonic carci-
noma cells and some cells of the spleen, thymus, bone
marrow and intestine in the adult mouse may fall into
the “stem cell” category, but the correlation will need to
be carefully tested [25,26]. Loss or mutation of nuclear
envelope proteins such as lamin A/C [27] or emerin [28]
causes muscular dystrophy, severe premature aging
(progeria) [29], and several additional diseases catalogued
as laminopathies [30], but a link between the nuclear
envelope protein deficiency with the deformed nuclear
morphology in cancer cells has not been established.
Loss of lamin A/C expression is often found in cancer
cells [26,31], including leukemia and lymphoma [32,33],
colon cancer [34,35], prostatic cancer [9], lung cancer
[36], and gastric cancer [37]. One study reported the
identification of high lamin A/C expression in a fraction
of ovarian cancer cases using high-density protein
microarrays [38]. However, normal ovarian surface
epithelial cells were also found to be high in lamin A/C
staining [38]. The observation may be explained by the
low fraction of epithelial cells relative to the total ovar-
ian tissue masses used for protein array analysis.
Recently, we found that the nuclear envelope protein
emerin is lost in a fraction of ovarian cancer cells [39].
Here, we further explored the expression of additional
nuclear envelope proteins in ovarian cancer and studied
the phenotypes for the loss of lamin A/C in ovarian
epithelial cells.
Materials and methods
Tumor specimens and immunohistochemistry
The current study utilized archived tumor tissues and
cell lines prepared from human ovaries obtained from
prophylactic surgeries. The tissues and cells lines were
obtained from Fox Chase Cancer Center tumor bank.
These tissues are designed for research only and contain
no link to personal information of the donors. The
study was reviewed by the Institutional Review Board
(IRB) of both Fox Chase Cancer Center and the Univer-
sity of Miami Miller School of Medicine, and was
approved and judged as non-human subject research.
The three ovarian tumor tissue microarrays (duplicate
core of 120 tumor tissues and 5 controls) and 20 prophy-
lactic oophorectomies were provided by the Tumor Bank
of Fox Chase Cancer Center. These ovarian tissues and
tumor specimens were described in more detail previously
[40,41]. Immunostaining was performed using the mouse
DAKO Envision TM+ System and the Peroxidase (DAB)
Kit (Dako Carpinteria, CA) as previously described
[24-26]. Negative controls were performed by replacing
the primary antibodies with non-immunized IgG.
Human ovarian surface epithelial and cancer cell cultures
Human ovarian surface epithelial (HOSE) cells were
established from ovaries obtained from prophylactic
oophorectomies [41]. The donors were usually indivi-
duals who were either BRCA1/2 carriers or had a family
history of breast or ovarian cancer but there was no
indication of cancer at the time of surgery. Each fresh
specimen of intact whole ovary from surgeries was
immersed in medium and the ovarian surface was gently
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scraped with a rubber policeman to collect cells. The ovar-
ian tissues were then subjected to histology analysis by
pathologists to confirm the absence of microscopic
tumors. HOSE cells were transfected with SV40 T-antigen
to prepare human “immortalized” ovarian (HIO) cells.
These HIO cells have a longer lifespan in culture and
can be cultured for 20 to 50 passages before undergoing
senescence, compared to HOSE cells that can only be
maintained for 5 to 7 passages [42,43].
Ovarian epithelial cancer cell lines were cultured in
(D)MEM with 10% FBS as previously reported [42,43].
The OVCAR lines were previously established by Tho-
mas Hamilton [42] and the others (A1847, A2780, ES2,
and SKOV-3) were obtained from American Type
Culture Collection.
Probes for Northern blot and antibodies for Western blot
Probes for lamin A/C, emerin, and lamin B1 were
obtained by reverse transcriptase-polymerase chain reac-
tion (PCR) using total RNA extracts from HOSE cells at
passage 2 as a template. The ascension number, sense
primer (SP), and anti-sense primer (ASP) are as follow-
ing: lamin B1 (BC078178): cggtg tacat cgaca aggtg (SP),
cagct gttgc tgcat ttgat (ASP); BAF (BC005942); gaacc
gttac gggaa ctgaa (SP), tcaaa cggat tgaaa gtgag g (ASP);
and lamin A/C (NM_005572): tctgc tgaga ggaac agcaa
(SP), ggtga tggag caggt catct (ASP). The PCR products
were sequenced to confirm the identity.
Mouse anti-emerin, rabbit anti-p21, and goat anti-
lamin B antibodies were purchased from Santa Cruz
Biotechnology Inc (Santa Cruz, CA). Anti-p53 mouse
IgGs were purchased from Dako (Carpinteria, CA) and
mouse anti-beta-tubulin from Sigma St. Louis, MO.
Small interfering RNA (shRNA) transfection
siRNA oligos and shRNA plasmids directed against
human lamin A/C were purchased from Santa Cruz Bio-
technology and were transfected into cells using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA) according to
the manufacturer’s protocol. Cells were retrieved
72 hours after transfection for analysis by Western blot,
Northern blot, or immunofluorescence microscopy.
Flow cytometry analysis
For sorting of live cells, 0.5 μM vybrant violet dye
(Molecular Probe) was added and incubated for 30 min-
utes at 37°C. For fixed cell analysis, the trypsinized cells
were resuspended in ice-cold ethanol/PBS (70% v/v) and
kept at -20°C until ready to use. Before flow cytometry
analysis, the fixed cells were resuspended in 0.5 μM
vybrant violet dye or propidium iodide and RNase A
solution. Cell sorting and flow analyses were performed
on a LSR Fortessa driven by BD’s FACS Diva software,
version 6.1.3 (Becton Dickinson, San Jose, CA).
Immunofluorescence microscopy
Cells were fixed with 4% paraformaldehyde, permeabi-
lized with 0.5% Triton X-100 for 5 minutes, blocked
with 3% BSA in PBS containing 0.1% Tween-20 for
30 minutes, incubated for 1 hour at 37°C with primary
antibodies, and subsequently with secondary antibodies
conjugated with AlexaFluor 488 (green fluorescence) or
AlexaFluor 594 (red fluorescence) (Molecular Probes/
Invitrogen, Carlsbad, CA). The nuclei were stained with
Hoechst 33342 (Molecular Probes). Cells were
mounted/sealed in anti-fade reagent containing 0.1 M
n-propyl gallate (pH 7.4) and 90% glycerol in PBS.
A Zeiss microscope and AxioCam Camera and
AxioVision software 4.8 were used for image acquisition.
Cytogenetic analysis
Chromosome number counting and fluorescence in situ
hybridization (FISH) analysis were performed by the
University of Miami Cytogenetic Core Facility. Briefly,
the cells were exposed to colcemid (demecolcine) (0.015
mg/ml) for 12 hours, resuspended in 10 ml hypotonic
buffer (75 mM KCl) for 20 minutes, and then kept in
1 ml of chilled fixative (methanol/acetic acid, 3/1). The
cell suspension was dropped on wet slides and heated
(70°C) overnight, dyed with Wright stain, and analyzed
to count 50 metaphases for each sample in duplicate.
For FISH analysis, an alpha-satellite DNA probe for
chromosome X centromeres (Xp11.1-q11.1) and a probe
for chromosome Y satalite III (Yq12) were used in inter-
phase cells. The pre-labeled FISH probes were pur-
chased from Abbott Molecular (Abbott Park, Illinois,
USA).
Results
Lamin A/C expression is frequently lost in ovarian cancer
cells and tissues
Since the nuclear envelope structural protein emerin
was found lost in a fraction (38%) of ovarian cancer
[39], we examined if the expression of other nuclear
envelope proteins might account for nuclear morpholo-
gical deformation of emerin-expressing ovarian cancer
cells. First, the expression of several nuclear envelope
proteins was investigated by Northern blot in a panel of
ovarian surface epithelial cells and cancer cell lines
(Figure 1A). mRNA for lamin B1 and emerin was found
to be generally higher in ovarian cancer and immorta-
lized (HIO) cells than primary human ovarian surface
epithelial (HOSE) cells (Figure 1A). Lamin A/C mRNA
is expressed in some but is reduced in other (OVCAR2
and A2780) ovarian cancer cells. We noticed that lamin
A but not lamin C mRNA is missing in HOSE981 cells,
though information is not available for us to correlate
with potential disease or phenotype of the individual.
For proteins, emerin is often missing or reduced in
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ovarian cancer lines as reported previously [39], and
noticeably, lamin A/C proteins are generally reduced in
ovarian cancer cells (Figure 1B). It appears that emerin
mRNA but not protein level is often increased in
“immortalized” ovarian epithelial and ovarian cancer
cells, and the expression of emerin mRNA and protein
levels do not correlate. Thus, we conclude that in ovar-
ian cancer cells emerin is lost/reduced at the protein
but not the mRNA level; and lamin A and lamin C are
reduced both at the mRNA and protein levels.
Next, we examined human ovarian tumors for lamin
A/C expression by immunohistochemistry. Normal ovar-
ian tissues show strong and uniform lamin A/C staining
around the nuclear envelope of all ovarian surface
epithelial cells (Figure 2A). Out of 108 informative ovar-
ian carcinomas [see Additional file 1: Table S1], we
found that 51 (47%) lack lamin A/C expression in
epithelial tumor cells, while on the same field of the
slide some stromal cells are positive, as shown in two
examples (Figure 2B). Additionally, the majority of ovar-
ian carcinomas that were catalogued as lamin A/C posi-
tive, contain a fraction of lamin A/C-negative cells
intermingling with lamin A/C-positive cells [see Addi-
tional file 1: Table S1], as shown by an example (Figure
2C). Another case is shown for an area containing both
normal ovarian surface epithelial cells and neoplastic
cells, which shows that the loss of lamin A/C correlates
closely with neoplastic transformation and an increase
in nuclear size (Figure 2D). Also, emerin staining in the
same area from an adjacent section becomes cytoplas-
mic instead of at the nuclear envelope, accompanying
the loss of lamin A/C (Figure 2E). The correlation
between loss of lamin A/C expression and emerin cellu-
lar distribution is consistent with the fact that lamin A
is essential for nuclear envelope localization of emerin
[44]. We conclude that the loss or abnormal distribution
of lamin A/C occurs in a significant percentage (47%) of
human ovarian cancers, and the rest show a variable
degree of loss of lamin A/C expression in a fraction of
tumor cells [see Additional file 1: Table S1]. Thus, in
addition to the previous reports for leukemia [32] and
B-cell lymphomas [33], colon cancer [34,35], prostatic
cancer [9], lung cancer [36], and gastric cancer [37],
lamin A/C is also often lost or reduced in ovarian
cancer.
Most ovarian cancer cells and tissues have a
heterogeneous Lamin A/C protein expression pattern
Furthermore, the tumors grouped as lamin A/C-positive
usually also contain a fraction of lamin A/C-negative
cells, ranging from 10% to 40% [see Additional file 1:
Table S1]. In contrast, all ovarian epithelial cells in nor-
mal tissues have strong lamin A/C staining around the
nuclear envelope (Figure 2A). Thus, nearly all ovarian
cancer cases have some degrees of nuclear envelope
structural defect due to the loss of lamin A/C (reported
here) or emerin [39] protein in a fraction to all of the
tumor cell population.
Figure 1 Expression of nuclear envelope proteins in ovarian epithelial and cancer cell lines. Primary non-cancer cells and cancer cell lines
were analyzed for mRNA and protein expression of nuclear envelope proteins lamin A/C, lamin B1, and emerin. (A) Total RNA was isolated and
analyzed by Northern blot of primary human ovarian surface epithelial cells (HOSE166, HOSE981, HOSE663, HOSE294, and HOSE388),
immortalized lines (HIO118, HIO114, HIO107, HIO105, HIO80), and ovarian cancer cells (OVCAR8, OVCAR4, OVCAR3, OVCAR5, and A2780) for the
expression of lamin A/C, lamin B1, and emerin. (B) Total cell lysates from two lines of primary ovarian surface epithelial cells (HOSE18, HOSE72),
an immortalized line (HIO60), and six ovarian cancer lines (OVCAR3, OVCAR5, OVCAR10, A2780, A1847, and ES2), were prepared from cultures for
Western blot analysis.
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Using immunofluorescence microscopy, we examined
the presence of lamin A/C in individual cells in culture.
In primary HOSE cells, all the cells (100%) stained
strongly for lamin A/C, showing a smooth and oval-
shaped nuclear morphology (Figure 3A). In all lines of
cancer cells examined, lamin A/C is lost in some lines,
or the expression is heterogeneous in the cell popula-
tion. For example, in OVCAR5 and A2780 ovarian can-
cer cells, lamin A/C is detectable but weak by Western
blot (Figure 1B); however, most of the cells are negative
and only a small fraction of positive cells are present, as
detected by immunofluorescence microscopy (Figure 3).
Lamin A/C suppression in human ovarian epithelial cells
causes nuclear morphological deformation
To explore the potential role of the loss of lamin A/C in
ovarian cancer, we investigated the consequence of
lamin A/C suppression in HOSE cells. Suppression of
lamin A/C proteins with siRNA oligonucleotides was
achieved as indicated by Western blot analysis (Figure
4A). We noticed a dramatic occurrence of cells with
large and irregularly shaped nuclei two to three days
after targeting lamin A/C, but not lamin B, with siRNA
(Figure 4B). Nuclei with chromatin bridges, conjoined,
and heart-shape appearance are common in lamin A/C-
suppressed cells (Figure 4C). In several experiments
using multiple HOSE cell preparations, lamin A/C down
regulation consistently resulted in around 50% of the
cells having large and atypical nuclear morphology. Con-
versely, cells transfected with control siRNA exhibited
mostly smooth, round or oval shaped nuclei with less
than 4% of cells having atypical nuclei. The extent of
lamin A/C down regulation on nuclear size and mor-
phology was quantified by computer-assisted imaging
analysis, and the results indicated that lamin A/C down
regulation caused a drastic change in nuclear shape
(Figure 4D). In comparison, down regulation of emerin
caused nuclear morphological deformation in around
20% of cells, consistent with our previous report [39].
The nuclear sizes of the cell population also changed
upon lamin A/C suppression (Figure 4E), as determined
using computer software (AxioVision software 4). The
diameter of the nucleus had a range of 13 to 29 μm in
HOSE cells and shifted up to 16 to 38 μm in the lamin
A/C-suppressed cells (Figure 4E). The average size
increased from 18 to 29 μm upon lamin A/C suppres-
sion, and the change was found statistically significant
(P < 0.005). Following lamin A/C suppression in HOSE
cells, the nuclear size distribution of the cell population
resembles OVCAR5 ovarian cancer cells (Figure 4E).
The variation in nuclear size may be caused by chroma-
tin organization, condensation, and DNA content.
Figure 2 Loss of lamin A/C expression in ovarian cancers. Ovarian normal and tumor tissues were analyzed by immunostaining for lamin
A/C. (A) A representative example shows that lamin A/C is strongly stained around the nucleus of normal ovarian surface epithelial cells. The
nuclei are generally smooth and oval-shaped in all normal ovarian surface epithelial cells. (B) Two examples show loss of lamin A/C expression in
ovarian carcinomas. Some stromal cells show strong lamin A/C staining around the nucleus, serving as an internal positive control. The nuclear
morphology of tumor cells is heterogeneous, and some cells with large and deformed nuclei are present. (C) A representative example of
ovarian carcinomas showing heterogeneous expression of lamin A/C among the tumor cells. (D) An example of ovarian carcinomas contiguous
with the benign ovarian surface epithelium. Lamin A/C is lost in the transformed cells. In an adjacent section, the loss of lamin A/C correlates
with the distribution of emerin to the cytoplasm of tumor cells.
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Figure 3 Heterogeneous lamin A/C expression in ovarian cancer cells. Lamin A/C expression in ovarian normal and cancer epithelial cells
was analyzed by immunofluorescence microscopy for DAPI (blue) and lamin A/C (red). Primary ovarian surface epithelial (HOSE) cells exhibit a
uniform staining pattern for lamin A/C. All ovarian cancer cell lines show heterogeneous staining of lamin A/C within the cell population, as
shown in examples, the OVCAR5 and A2780 ovarian cancer cells.
Figure 4 Suppression of lamin A/C expression in ovarian surface epithelial cells leads to a deformed nuclear shape. Primary HOSE cells
were treated with siRNA to lamin A/C for three days and were analyzed for the effect on nuclear size and morphology. (A) Western blot shows
the specific suppression of protein by siRNA to emerin, lamin A/C, and lamin B1 in primary HOSE cells. (B) A low magnification image (× 200)
shows the presence of a high percentage of cells with large and deformed nuclear morphology following suppression of lamin A/C by siRNA in
primary HOSE cells for three days. Suppression of lamin B had no significant effect on nuclear morphology. (C) Examples shown at high
magnification (× 1,000) of individual deformed nuclei with reduced and patchy lamin A/C staining. (D) The nuclear morphological abnormality
was scored by computer-assisted image analysis. About 100 nuclei in each group treated by siRNA were analyzed and the percentage of normal
and atypical nuclear morphology is shown. ScControl: scrambled controls. (E) The nuclear size/diameter was scored by computer-assisted image
analysis (AxioVision software 4) following shRNA treatment for 3 days. Nuclear sizes were plotted following computer-assisted imaging analysis of
50 nuclei randomly selected from each group, compared to OVCAR5 ovarian cancer cells.
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OVCAR5 has 51 to 57 chromosomes per cell http://
www.ncbi.nlm.nih.gov/sky/skyweb.cgi?form_type=sub-
mitters[13]. Thus, the experiments showed that the loss
of lamin A/C leads to atypical nuclear morphology and
increased nuclear size in HOSE cells, resembling those
of cancer cells. Similar to OVCAR5 cells, the increased
nuclear size distribution in lamin A/C-suppressed HOSE
cells was speculated to be caused by increased DNA
content and changes in chromatin organization. These
experiments have been repeated three times over a one-
year period using three independent preparations of
HOSE cells, and the reproducibility of the results was
very good.
Suppression of Lamin A/C leads to polyploidy and
aneuploidy in ovarian surface epithelial cells
Next, we analyzed cellular DNA content in HOSE cells
following lamin A/C suppression. First, we determined
the DNA content of the cell populations by flow
cytometry (Figure 5A). Lamin A/C-suppressed HOSE
cells exhibited a slight but recognizable shift in DNA
content compared to HOSE cells of both 2n and 4n
populations (Figure 5A). The subtle increases in cellular
DNA content upon lamin A/C suppression were com-
parable to those of OVCAR5 (51 to 57 chromosomes
per cell) and OVCAR3 (52 to 70 chromosomes per cell)
cells, performed in the flow cytometry as controls (Fig-
ure 5A). Thus, we conclude that the lamin A/C-sup-
pressed cells achieved aneuploidy and a chromosomal
distribution similar to the aneuploid ovarian cancer cells
(OVCAR5 and OVCAR3).
These cells were further analyzed by FISH using an X
centromere probe. Typically, the control cells showed
two X-chromosome markers per cell, indicating a
diploid ploidy (Figure 5B). Rare (less than one per 100
nucleus examined) tetraploid cells were observed, as
shown in an example (Figure 5B). In contrast, three to
four X-chromosomes per nucleus were detected in 37%
Figure 5 Lamin A/C suppression in primary ovarian epithelial cells results in increased nuclear size, aneuploidy, and polyploidy.
Primary HOSE cells were transfected with control or shRNA to suppress lamin A/C and were subjected to analysis for DNA content and ploidy.
(A) The shRNA-treated and control HOSE cells were sorted by flow cytometry to compare DNA content. Two aneuploid ovarian cancer cell lines,
OVCAR5 (51 to 57 chromosomes per cell) and OVCAR3 (52 to 70 chromosomes per cell) were analyzed for comparison. A subtle increase in DNA
content was observed in lamin A/C-suppressed HOSE cells. (B) In situ hybridization with X chromosome centromere probe of control HOSE cells
treated with scrambled shRNA. Two representative fields are shown. (C) In situ hybridization with X centromere probe of lamin A/C-suppressed
HOSE cells. Six representative fields are shown for the presence of 3, 4, and other multiple X-chromosome-containing nuclei.
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of the lamin A/C-suppressed HOSE cells, as shown in
examples from six images (Figure 5C). Thus, suppres-
sion of lamin A/C leads to the formation of tetraploid
and aneuploid ovarian epithelial cells. The wide distribu-
tion of nuclear sizes and the broad range of DNA con-
tents in the lamin A/C-suppressed cells is consistent
with a variation of chromosomal numbers and aneu-
ploidy of the cells; however, we were not able to deter-
mine the exact chromosomal number in each cell due
to difficulty in obtaining a sufficient number of mitotic
cells (discussed below).
Suppression of Lamin A/C leads to reduced mitosis and
retarded cell growth
In several attempts to analyze the exact chromosome
number by cytogenetic approach, we failed to collect a suf-
ficient number of mitotic nuclei in lamin A/C-suppressed
cells, while control cells readily formed metaphase spreads.
This observation suggests that suppression of lamin A/C
may interfere with cell proliferation and normal mitosis.
We performed flow cytometry to analyze simultaneously
DNA content (Figure 6A) and bromodeoxyuridine (BrdU)
incorporation as an indicator of DNA synthesis
(Figure 6B) in the same cell population. Indeed, in lamin
A/C-suppressed HOSE cells, 75% of the cells have DNA
content higher than 2n, but only 5.1% of the cells had high
BrdU incorporation. In comparison, 23% of the control
cells had DNA content higher than 2n, and 15% of the
cells had high BrdU uptake. These results indicate that
the lamin A/C-suppressed cells were aneuploid or poly-
ploid, and were not in S-phase or actively undergoing
replication.
Although the primary HOSE cells proliferated slowly in
culture (compared to cancer cells), we observed that
about 12% of the control cells in culture were undergoing
mitosis using beta-tubulin staining to mark the mitotic
spindles (Figure 6C). In contrast, mitotic spindles were
rare (< 1%) in lamin A/C-suppressed cells (Figure 6D),
indicating a reduced cell division following the loss of
lamin A/C and aneuploidy. It is known that the p53/p21
pathway is activated to mediate growth arrest of aneu-
ploid cells [45]. Indeed, we found that p53 and p21 pro-
teins were increased in lamin A/C-suppressed, aneuploid
cells (Figure 6E). The induced cell cycle inhibitor p21 fol-
lowing lamin A/C-suppression is p53-dependent, since
simultaneous suppression of both lamin A/C and p53 did
not stimulate an increased p21 expression. It was rea-
soned that the lamin A/C-suppressed and aneuploid cells
Figure 6 Lamin A/C suppression in primary ovarian epithelial cells results in growth retardation. Primary HOSE cells were transfected
with control or shRNA to suppress lamin A/C expression. The cells were analyzed for DNA content and bromodeoxyuridine (BrdU) incorporation
simultaneously by flow cytometry. (A) Primary HOSE cells were analyzed by flow cytometry for DNA content following treatment with control or
lamin A/C shRNA for three days. Lamin A/C-suppressed cells have > 2n DNA in 75% of cells, compared to 23% of control cells. (B) The same cell
populations were incubated with BrdU for one hour in culture, and then fixed and stained with FITC-anti-BrdU prior to flow cytometry to
determine BrdU incorporation as an indicator of proliferation. (C) The control cells show a high percentage of mitotic nuclei as shown by
immunofluorescence microscopy of beta-tubulin staining of the mitotic spindles. (D) In comparison, beta-tubulin-immunostained mitotic spindles
are rare in lamin A/C-suppressed cells. (E) The HOSE cells were treated with siRNA-p53 and/or siRNA-lamin A/C for three days and then analyzed
for p53 and p21 by Western blot.
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might overcome growth arrest once p53 function is lost,
and future experiments are to determine the long-term
consequence of lamin A/C suppression in the absence
of p53.
Discussion
A significant understanding of ovarian cancer biology
and genetics has been achieved [46,47], though the
causes and importance of chromosomal instability as
well as nuclear atypia are still topics of research. We
found that lamin A/C is absent in a significant fraction
of ovarian (47%) cancers. Intriguingly, most ovarian
carcinoma tissues and cancer cell lines exhibit a hetero-
geneous pattern of lamin A/C expression in the popula-
tion of cancer cells, which may account for the variation
of nuclear shapes within an ovarian tumor. Lamin A/C
expression is regulated during cell differentiation and
embryonic development, but the expression is not
known to be regulated in a cell cycle-dependent manner
[25,26]. Thus the heterogeneous lamin A/C expression
in cancer cells may link to heterogeneity of tumor cells.
Despite its being such a prominent feature of malig-
nancy, what role a deformed nucleus may play in the
development of cancer is unclear. The identification of
the loss of nuclear envelope structural proteins emerin
and lamin A/C as the molecular basis of nuclear defor-
mation in cancer cells may provide some explanation.
We found that suppression of emerin [39] or lamin A/C
(current study) lead to mitotic failure and the formation
of polypoid and subsequent aneuploid cells. The essen-
tial role of lamin A/C in mitosis and the formation of
the envelope to house the newly formed nuclei in divid-
ing cells have been shown in Caenorhabditis elegans
[48,49], which has only one lamin gene. Lamin suppres-
sion results in the formation of chromatin bridges, large
and deformed nuclei, and ultimately developmental fail-
ure [49]. Emerin suppression only slightly affects cell
division and its role is redundant with MAN gene in
C. elegans [50].
In mammals, neither lamin A/C [51] nor emerin
[52,53] is essential for cell division and development as
shown by gene knockout in mice. However, lamin A/C-
deficient cells exhibit a phenotype of chromosomal
numerical instability, though the mechanism was not
analyzed [54]. Mutations in the lamin A/C gene have
also been shown to affect cell cycle and mitosis in
human cells [55,56]. We also report an increased mitotic
failure and the formation of polyploidy and aneuploidy
in HOSE cells when emerin expression is suppressed
[39]. In the current study, we conclude that though
lamin A/C is not essential for the initial division of
ovarian epithelial cells in culture, nevertheless, the loss
of lamin A/C increases mitotic failure and the develop-
ment of polyploidy and subsequent aneuploidy. We
further speculate that nuclear structural defects as a
consequence of the loss of lamin A/C (and also loss of
emerin) may be a principal mechanism for the chromo-
somal numerical instability, and the underlying cause of
aneuploidy in ovarian cancer. Since lamin A/C expres-
sion has been found to be lost in several cancer types
[31], loss of lamin A/C expression may be the possible
common cause of nuclear atypia and chromosomal
numerical instability observed in many cancer types.
A characteristic of laminopathies (disorders caused by
mutated and defective lamin A/C) is genomic instability
[30,54], which is shared by cancer. However, laminopa-
thies are not linked to a predisposition to cancer. In
fact, we observed that suppression of lamin A/C results
in a lowered rate of mitosis and cell growth, coincident
with polyploidy and aneuploidy. We reasoned that loss
of lamin A/C and subsequent aneuploidy by itself is not
oncogenic, but actually reduces the efficiency in cell
division and proliferation. Aneuploidy is not tolerated in
development, has severe consequences on cell prolifera-
tion, and can be detrimental to individual normal cells
[57,58]. However, with additional oncogenic changes
(such as p53 mutation) to bypass cell growth regulation
and cellular stress, chromosomal instability brought by
the loss of nuclear structural integrity may enable the
cells to undergo oncogenic evolution and development
of malignant tumors [59,60]. Thus, neoplastic cells may
acquire a nuclear structural defect and trade cell growth
efficiency for versatility and agility in chromosomal
instability. Indeed, ovarian cancer accumulates vast
amounts of seemingly random genomic changes [13,61],
indicative of chromosomal numerical instability. Both
p53 mutation and acquisition of aneuploidy are closely
associated early events [18,62], and p53 mutation is
common in high-grade ovarian cancer [46,47,63,64],
allowing the survival and proliferation of aneuploid cells.
Aneuploidy activates the p53/p21 pathway [45].
Indeed we found that p53 and p21 are increased in
lamin A/C-suppressed cells, presumably mediating the
observed cell growth arrest. In our experiments, unfor-
tunately, the siRNA-suppression of p53 is short-lived,
not permitting our study to determine if loss of both of
p53 and lamin A/C might allow survival of aneuploid
cells and the selection of clones with a chromosomal
composition presenting a neoplastic phenotype. Proper
experimental systems (mutant mice) are currently under
development to test this hypothesis.
Conclusions
In summary, we report the finding of the frequent loss
and aberrant expression of lamin A/C in ovarian cancer.
The experimental results support that a nuclear envel-
ope structural defect caused by the loss of lamin A/C
may be the molecular basis of two of the prominent
Capo-chichi et al. BMC Medicine 2011, 9:28
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hallmarks of human cancer, nuclear morphological
deformation and aneuploidy.
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